Non-Hodgkin Lymphoma
Conditions
Keywords
Non-Hodgkin lymphoma, rituximab, immunotherapy
Brief summary
The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.
Detailed description
Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy. It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy. In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit. We will prospectively treat a group of patients with the following characteristics: \< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen: R-CHOP (standard dosis) for 8 cycles
Interventions
DRUGRituximab
Sponsors
Instituto Nacional de Cancerologia de Mexico
Study design
Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+ * BCL-6 negative * Age \< 61 years old * ECOG 2 or less * IPI low, low intermediate * Stage II, III or IV * Signed Informed Consent
Exclusion criteria
* Stage I * Previous treatment * Lymphomatous central nervous system involvement * Heart disease * Kidney failure (serum creatinine \> 2 mg/dl) * HIV + * Viral Hepatitis * Pregnancy
Countries
Mexico
Contacts
Primary ContactSilvia Rivas-Vera, MD
Backup ContactPedro Sobrevilla-Calvo, MD
Outcome results
None listed